Tearsheet

Haemonetics (HAE)

Market Price (4/10/2026): $58.42 | Market Cap: $2.7 Bil
Sector: Health Care | Industry: Health Care Supplies

Haemonetics (HAE)

Market Price (4/10/2026): $58.42
Market Cap: $2.7 Bil
Sector: Health Care
Industry: Health Care Supplies

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.4%, FCF Yield is 11%

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 26%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 23%

Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, Digital Health & Telemedicine, and Automation & Robotics. Themes include Geriatric Care, Show more.

Weak multi-year price returns
2Y Excs Rtn is -64%, 3Y Excs Rtn is -95%

Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -4.0%, Rev Chg QQuarterly Revenue Change % is -2.7%

Key risks
HAE key risks include [1] mounting competitive pressure on its VASCADE devices from specific rival products and [2] significant customer concentration in its vital plasma business, Show more.

0	Attractive yield Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.4%, FCF Yield is 11%
1	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 26%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 23%
2	Megatrend and thematic drivers Megatrends include Aging Population & Chronic Disease, Digital Health & Telemedicine, and Automation & Robotics. Themes include Geriatric Care, Show more.
3	Weak multi-year price returns 2Y Excs Rtn is -64%, 3Y Excs Rtn is -95%
4	Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -4.0%, Rev Chg QQuarterly Revenue Change % is -2.7%
5	Key risks HAE key risks include [1] mounting competitive pressure on its VASCADE devices from specific rival products and [2] significant customer concentration in its vital plasma business, Show more.

Valuation, Metrics & Events

	4/10/26	2025	2024	2023	2022
Share Price CYE	$58.42	$63.55	$85.35	$82.75	$63.22
Market Cap CYE ($ Bil)	2.7	3.1	4.3	4.2	3.2
Total Debt ($ Bil)	1.2	1.2	0.8	0.8	0.8
Total Cash ($ Bil)	0.4	0.3	0.2	0.3	0.3
Enterprise Value ($ Bil)	3.6	4.3	5.1	5.0	4.0
Valuation Ratios
P/S TTM	2.1	2.3	3.3	3.6	3.3
P/EBIT TTM	10.9	14.1	26.3	26.8	40.0
P/E TTM	15.6	18.6	36.9	36.2	74.5
P/FCF TTM	8.9	21.9	30.2	51.1	42.7
Sector Ratios
P/S TTM (Sector)	3.7	3.3	4.1	4.3	6.0
P/EBIT TTM (Sector)	-1.7	-1.3	-1.7	-1.3	-2.2
P/E TTM (Sector)	-1.8	-1.3	-2.0	-1.5	-2.2
P/FCF TTM (Sector)	-1.7	-1.2	-2.0	-1.5	-2.5

	4/10/26	2025	2024
Share Price CYE	$58.42	$63.55	$85.35
Market Cap CYE ($ Bil)	2.7	3.1	4.3
Total Debt ($ Bil)	1.2	1.2	0.8
Total Cash ($ Bil)	0.4	0.3	0.2
Enterprise Value ($ Bil)	3.6	4.3	5.1
Valuation Ratios
P/S TTM	2.1	2.3	3.3
P/EBIT TTM	10.9	14.1	26.3
P/E TTM	15.6	18.6	36.9
P/FCF TTM	8.9	21.9	30.2
Sector Ratios
P/S TTM (Sector)	3.7	3.3	4.1
P/EBIT TTM (Sector)	-1.7	-1.3	-1.7
P/E TTM (Sector)	-1.8	-1.3	-2.0
P/FCF TTM (Sector)	-1.7	-1.2	-2.0

	HAE	S&P 500
REVENUE GROWTH	VERY POOR
Rev LTM ($ Bil)	1.3
Rev Chg Q	-2.7%	7.4%
Rev Chg LTM	-4.0%	6.8%
Rev Chg 3Y Avg	5.5%	5.7%
PROFITABILITY	FAIR
Op Inc LTM ($ Bil)	0.2
CFO LTM ($ Bil)	0.3
Net Inc LTM ($ Bil)	0.2
Op Mgn LTM	18.0%	18.6%
CFO/Rev LTM	25.7%	20.7%
Net Inc Mgn	13.3%	12.8%
VALUATION	MODERATE
P/S	2.1	3.3
P/CFO	8.1	15.6
P/FCF	8.9	20.2
P/E	15.6	24.3
STABILITY	GOOD
Debt/Equity	0.45	0.21
Cash/Assets	0.15	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Revenue by Plasma Segment	125400000	9272025	Link
Revenue by Hospital Segment	145500000	9272025	Link
Revenue by Blood Center Segment	56500000	9272025	Link
Organic Revenue Growth (excluding CSL impact)	9.4%	9272025	Link
Number of Common Stock Shares Repurchased	1430579	9272025	Link
Revenue Percentage from Ten Largest Customers	42%	3292025	Link
Number of Employees	3023	3292025	Link

Upcoming
5/07/2026	Earnings Release	Rev: $337 Mil (E) EPS: $1.28 (E)

Price Chart

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Haemonetics (HAE) stock has lost about 25% since 12/31/2025 because of the following key factors:

1. Haemonetics's reaffirmed fiscal year 2026 revenue guidance projected a reported decline of 3% to 6%, despite the company beating Q1 FY2026 earnings estimates. This guidance, announced on August 7, 2025, contributed to a significant 21.85% drop in the stock price in pre-market trading, as it highlighted ongoing business pressures and signaled a challenging outlook for the fiscal year. The anticipated decline was largely due to portfolio transitions, including the divestiture of the Whole Blood business, the CSL transition, and the exit of certain liquid solution products, which represented a $153 million headwind.

2. Weakness in the Interventional Technologies (IVT) segment negatively impacted overall performance. The Interventional Technologies franchise experienced a 7% decline in revenue during Q1 FY2026 due to factors such as OEM destocking and pressures related to Peripheral Field Anesthesia (PFA). This underperformance partially offset stronger growth observed in the Blood Management Technologies segment, leading to concerns about the company's ability to maintain momentum in certain hospital-focused areas.

Show more

Stock Movement Drivers

Fundamental Drivers

The -27.1% change in HAE stock from 12/31/2025 to 4/9/2026 was primarily driven by a -31.3% change in the company's P/E Multiple.

(LTM values as of)	12312025	4092026	Change
Stock Price ($)	80.15	58.42	-27.1%
Change Contribution By:
Total Revenues ($ Mil)	1,328	1,318	-0.7%
Net Income Margin (%)	12.7%	13.3%	5.1%
P/E Multiple	22.7	15.6	-31.3%
Shares Outstanding (Mil)	48	47	1.7%
Cumulative Contribution			-27.1%

LTM = Last Twelve Months as of date shown

Market Drivers

12/31/2025 to 4/9/2026

	Return	Correlation
HAE	-27.1%
Market (SPY)	-5.4%	-6.0%
Sector (XLV)	-3.5%	5.9%

Fundamental Drivers

The 19.9% change in HAE stock from 9/30/2025 to 4/9/2026 was primarily driven by a 9.7% change in the company's Net Income Margin (%).

(LTM values as of)	9302025	4092026	Change
Stock Price ($)	48.74	58.42	19.9%
Change Contribution By:
Total Revenues ($ Mil)	1,346	1,318	-2.1%
Net Income Margin (%)	12.1%	13.3%	9.7%
P/E Multiple	14.4	15.6	8.5%
Shares Outstanding (Mil)	48	47	2.8%
Cumulative Contribution			19.9%

LTM = Last Twelve Months as of date shown

Market Drivers

9/30/2025 to 4/9/2026

	Return	Correlation
HAE	19.9%
Market (SPY)	-2.9%	-2.4%
Sector (XLV)	7.8%	11.8%

Fundamental Drivers

The -8.1% change in HAE stock from 3/31/2025 to 4/9/2026 was primarily driven by a -36.6% change in the company's P/E Multiple.

(LTM values as of)	3312025	4092026	Change
Stock Price ($)	63.55	58.42	-8.1%
Change Contribution By:
Total Revenues ($ Mil)	1,374	1,318	-4.0%
Net Income Margin (%)	9.5%	13.3%	40.5%
P/E Multiple	24.6	15.6	-36.6%
Shares Outstanding (Mil)	50	47	7.5%
Cumulative Contribution			-8.1%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2025 to 4/9/2026

	Return	Correlation
HAE	-8.1%
Market (SPY)	16.3%	22.6%
Sector (XLV)	3.7%	27.7%

Fundamental Drivers

The -29.4% change in HAE stock from 3/31/2023 to 4/9/2026 was primarily driven by a -64.3% change in the company's P/E Multiple.

(LTM values as of)	3312023	4092026	Change
Stock Price ($)	82.75	58.42	-29.4%
Change Contribution By:
Total Revenues ($ Mil)	1,129	1,318	16.7%
Net Income Margin (%)	8.5%	13.3%	56.9%
P/E Multiple	43.6	15.6	-64.3%
Shares Outstanding (Mil)	51	47	7.9%
Cumulative Contribution			-29.4%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2023 to 4/9/2026

	Return	Correlation
HAE	-29.4%
Market (SPY)	63.3%	23.6%
Sector (XLV)	20.8%	27.8%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
HAE Return	-55%	48%	9%	-9%	3%	-26%	-50%
Peers Return	9%	-25%	-12%	4%	1%	-4%	-29%
S&P 500 Return	27%	-19%	24%	23%	16%	-1%	81%
Monthly Win Rates [3]
HAE Win Rate	42%	67%	58%	42%	33%	25%
Peers Win Rate	45%	38%	42%	48%	47%	60%
S&P 500 Win Rate	75%	42%	67%	75%	67%	50%
Max Drawdowns [4]
HAE Max Drawdown	-58%	-17%	-8%	-17%	-39%	-33%
Peers Max Drawdown	-9%	-34%	-26%	-13%	-25%	-10%
S&P 500 Max Drawdown	-1%	-25%	-1%	-2%	-15%	-7%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: ICUI, LIVN, BAX, BDX, MDT. See HAE Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/9/2026 (YTD)

How Low Can It Go

Unique Key	Event	HAE	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-68.6%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	218.7%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-39.0%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	63.9%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	294 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-29.9%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	42.7%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	63 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-25.3%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	33.9%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	707 days	1,480 days

Compare to ICUI, LIVN, BAX, BDX, MDT

In The Past

Haemonetics's stock fell -68.6% during the 2022 Inflation Shock from a high on 2/8/2021. A -68.6% loss requires a 218.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Haemonetics (HAE)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

AI Analysis | Feedback

It's like BD (Becton, Dickinson and Company) for specialized blood and plasma collection and management solutions.

Think of it as a highly focused Thermo Fisher Scientific for blood and plasma processing, diagnostics, and patient care.

AI Analysis | Feedback

NexSys PCS and PCS2: Automated plasmapheresis equipment and associated disposables for plasma collection.
NexLynk DMS: An integrated information technology platform for managing plasma donors, operations, and supply chain.
MCS brand apheresis equipment: Automated systems for collecting specific blood components from donors.
Disposable whole blood collection and component storage sets: Products used for manual whole blood collection and storing blood components.
SafeTrace Tx and El-Dorado Donor: Management systems for blood donations and blood units.
TEG diagnostic systems: Point-of-care and laboratory systems that assess a patient's coagulation status.
Cell Saver Elite +: An autologous blood recovery system used in various surgical procedures.
BloodTrack: A suite of solutions combining software and hardware for blood management and bedside transfusion.

AI Analysis | Feedback

Haemonetics (HAE) primarily sells its products and solutions to other companies and organizations, rather than directly to individuals. The provided company description does not list the names of specific customer companies or their symbols.

However, based on the description of its three segments, Haemonetics' major customers fall into the following categories of organizational entities:

Plasma Collection Companies/Centers: These customers utilize Haemonetics' automated plasma collection devices, related disposables, software, and IT platforms (e.g., NexSys PCS, NexLynk DMS) to manage donors, operations, and supply chains for plasma collection.
Blood Centers and Blood Banks: Customers in this category use products such as automated blood component collection systems (e.g., MCS brand apheresis equipment), disposable whole blood collection and storage sets, and blood unit management software (e.g., SafeTrace Tx, Hemasphere) for donor management and blood processing.
Hospitals and Clinical Laboratories: This segment's customers include hospitals and their associated laboratories, which use products like TEG diagnostic systems for coagulation assessment, Cell Saver Elite + for autologous blood recovery during surgery, and BloodTrack solutions for blood management and bedside transfusions.

AI Analysis | Feedback

null

AI Analysis | Feedback

Christopher Simon, President and Chief Executive Officer

Christopher Simon was appointed President and Chief Executive Officer of Haemonetics in May 2016. He brings over 30 years of experience in healthcare. Prior to joining Haemonetics, he served as a Senior Partner at McKinsey & Company, where he led the Global Medical Products Practice. Earlier in his career, he held commercial and operating roles at Baxter Healthcare Corporation and served as a U.S. Army Infantry Officer. Mr. Simon holds a Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania and an MBA from Harvard Business School.

James C. D'Arecca, Executive Vice President, Chief Financial Officer

James C. D'Arecca joined Haemonetics as Executive Vice President, Chief Financial Officer in April 2022. He has nearly 30 years of experience in finance leadership and strategy. Before Haemonetics, Mr. D'Arecca was Chief Financial Officer of TherapeuticsMD, a women's healthcare company, from June 2020 to April 2022. He previously served as Senior Vice President and Chief Accounting Officer at Allergan plc (formerly Actavis plc) for nearly seven years until its merger with AbbVie Inc. in May 2020. His career also includes roles as Chief Accounting Officer at Bausch & Lomb and finance and business development positions at Merck & Co., Inc. and Schering-Plough. He began his career at PricewaterhouseCoopers, focusing on pharmaceuticals, medical devices, and consumer products. Mr. D'Arecca is a Certified Public Accountant and holds a Bachelor of Science in Accounting from Rutgers University and an MBA from Columbia University.

Michelle L. Basil, Executive Vice President, General Counsel

Michelle L. Basil serves as the Executive Vice President, General Counsel of Haemonetics.

Frank W. Chan, Ph.D., Executive Vice President, Chief Operating Officer

Frank W. Chan, Ph.D. joined Haemonetics as Executive Vice President, Chief Operating Officer in April 2025. He has over 25 years of experience in medical device and healthcare technology leadership, including delivering innovative solutions to market and leading business transformation. Prior to Haemonetics, he was President of Acute Care & Monitoring at Medtronic plc and held various roles at Covidien plc (acquired by Medtronic) and DePuy Orthopaedics, Inc. (a Johnson & Johnson company).

Roy Galvin, Executive Vice President, Chief Commercial Officer

Roy Galvin was appointed Executive Vice President, Chief Commercial Officer in March 2025. He originally joined Haemonetics in 2022 as President, Global Plasma and Blood Center. In his expanded role, he is responsible for the company's Global Hospital business, as well as Global Plasma and Blood Center, overseeing all commercialization initiatives.

AI Analysis | Feedback

The key risks to Haemonetics' business are:

Dependence on Plasma and Blood Donation Volumes and Regulatory Changes: A significant portion of Haemonetics' revenue is derived from its Plasma and Blood Center segments, which are directly reliant on the volume of plasma and whole blood donations. Any factors that negatively impact donor availability, such as public health crises, changes in donor eligibility criteria, or shifts in societal attitudes towards donation, could reduce demand for their collection devices, disposables, and donor management systems. Additionally, changes in regulatory policies regarding plasma collection, blood safety, or donor compensation could significantly affect these core business segments.
Intense Competition and Rapid Technological Advancements: Haemonetics operates in highly competitive markets across its Plasma, Blood Center, and Hospital segments. The medical device and healthcare IT industries are characterized by continuous innovation and evolving technologies. Competitors may develop more advanced, efficient, or cost-effective collection systems, diagnostic tools, or blood management software. The company's ability to maintain and grow its market share depends on its capacity for ongoing research and development, successful product innovation, and effective differentiation from competitors.
Supply Chain Risks for Critical Disposables: Many of Haemonetics' products, including those for plasma collection, blood component separation, and surgical blood recovery (e.g., Cell Saver Elite+), utilize proprietary disposable components. Disruptions in the supply chain for these critical disposables, such as raw material shortages, manufacturing delays, or geopolitical events, could significantly impact the company's ability to supply its customers, fulfill orders, and generate recurring revenue. This reliance on a steady and reliable supply of disposables makes the company vulnerable to various supply chain challenges.

AI Analysis | Feedback

null

AI Analysis | Feedback

Haemonetics Corporation (HAE) operates in several key medical technology markets, providing products and solutions across plasma, blood center, and hospital segments. The addressable markets for its main products and services include:

Plasma Collection Devices and Related Disposables (e.g., NexSys PCS, PCS2 plasmapheresis equipment): These products fall under the broader Apheresis Equipment Market. The global apheresis equipment market size was valued at approximately USD 3.51 billion in 2025 and is projected to increase to about USD 8.39 billion by 2035, exhibiting a Compound Annual Growth Rate (CAGR) of 9.11% from 2026 to 2035. North America held the largest share of this global market, accounting for 35% in 2025.
Automated Blood Component and Manual Whole Blood Collection Systems (e.g., MCS brand apheresis equipment, disposable whole blood collection sets): These products are part of the global Blood Collection Devices Market. This market was valued at USD 9.4 billion in 2025 and is projected to grow to USD 18.07 billion by 2034, at a CAGR of 7.53%. North America accounts for approximately 35% of the Blood Collection Devices Market.
TEG Diagnostic Systems: These are key components of the Thromboelastography Analyzer Market. The global thromboelastography analyzer market size was valued at USD 383 million in 2024 and is projected to reach USD 729 million by 2032, with a CAGR of 9.9%. North America dominates this market, holding a 37% share.
Cell Saver Elite+ (Autologous Blood Recovery System): This product is part of the Autotransfusion Systems Market. The global autotransfusion systems market size was over USD 534.6 million in 2025 and is estimated to reach USD 872.9 million by the end of 2035, growing at a CAGR of 5.6% during the forecast timeline. North America is projected to be the largest regional market, holding a 34.6% share by 2035.
BloodTrack (Blood Management and Bedside Transfusion Solutions): This falls under the Blood Management Software Market. This market was valued at USD 1.23 billion in 2025 and is estimated to grow to USD 2.05 billion by 2031, at a CAGR of 8.84%. North America accounted for 38.10% of the market revenue in 2025.

AI Analysis | Feedback

Haemonetics (HAE) anticipates several key drivers to fuel its revenue growth over the next two to three years:

Plasma Segment Expansion and Innovation: Growth in the Plasma segment is expected to be a primary driver, propelled by the continued adoption and innovation of its NexSys PCS system, particularly with the proprietary Persona Technology. This technology is designed to enhance plasma yield, improve operational efficiency in collection centers, and elevate the donor experience. The company foresees sustained strong performance in its Plasma business, supported by increasing global demand for plasma collections.
Hospital Segment Strength, particularly Blood Management Technologies: The Hospital business is projected to maintain robust growth, especially within its Blood Management Technologies portfolio. This includes the strong performance of TEG diagnostic systems and the increasing adoption of the heparinase neutralization cartridge in hemostasis management. Additionally, the VASCADE closure devices, including newer introductions like VASCADE MVP XL expanding into electrophysiology, are expected to continue contributing to revenue expansion within this segment.
New Product Launches and Research & Development: Haemonetics is committed to significant investment in research and development to expand its product offerings. Key anticipated launches that are expected to drive future revenue include an advanced whole blood automation system, designed to streamline blood collection and processing, and the U.S. launch of PerQseal Elite. The company's focus on developing next-generation technologies and AI-driven analytics platforms underscores its innovation-led growth strategy.
Geographical Market Expansion: The company is strategically targeting high-growth emerging markets for expansion, with a particular focus on the Asia-Pacific (APAC) region. This geographical diversification is a key initiative to broaden its customer base and generate additional revenue streams over the coming years.

AI Analysis | Feedback

Share Repurchases

In April 2025, Haemonetics' Board of Directors authorized a new share repurchase program of up to $500 million of common stock over the next three years to offset the dilutive impact of employee equity grants.
During fiscal year 2025, Haemonetics completed its prior $300 million share repurchase program, which included an accelerated share repurchase agreement for $150 million that resulted in the repurchase of approximately 2.4 million shares.
As of November 2025, the company completed a $75 million buyback, repurchasing 1,430,579 shares (approximately 2.97% of outstanding stock) under the May 2025 authorization.

Share Issuance

In May 2024, Haemonetics announced its intention to offer $525 million aggregate principal amount of Convertible Senior Notes due 2029 in a private offering, with an option for initial purchasers to acquire up to an additional $75 million. The proceeds are intended for capped call transactions, working capital, and general corporate purposes, including debt repayment.
In March 2021, the company priced an offering of $435 million aggregate principal amount of 0.00% Convertible Senior Notes due 2026, which was an increase from the previously announced $425 million. An option for an additional $65 million principal amount was also granted.
The total net proceeds from the sale of the 2026 Convertible Senior Notes were approximately $486.7 million.

Outbound Investments

In January 2026, Haemonetics acquired Vivasure Medical Limited in a transaction valued up to €185 million (approximately $215 million) upon the completion of certain milestones. Haemonetics had previously made a strategic investment in Vivasure Medical in 2022, which included an option to acquire the company.
In December 2023, Haemonetics completed the acquisition of OpSens Inc., a cardiology-focused medical device company, for approximately $255 million in an all-cash transaction. This acquisition expanded Haemonetics' presence in the interventional cardiology market.
In April 2024, the company acquired Attune Medical for $160 million, adding an Esophageal Protection product line and expanding its Hospital segment.

Capital Expenditures

Haemonetics' capital expenditures were $39.278 million in fiscal year 2025 and $38.125 million in fiscal year 2024.
The company's capital allocation strategy prioritizes funding planned internal investments to support growth.
Expected capital expenditures are estimated at $40 million for fiscal 2026, $41 million for fiscal 2027, and $42 million for fiscal 2028.

Interactive Breakdown

null

null

Better Bets vs. Haemonetics (HAE)

INDUSTRY: Health Care Supplies

Higher Rev Chg LTM (Value for HAE: -4.0%)

NVST (8.3%)

Envista

WST (6.3%)

West Pharmaceutical Services

COO (5.7%)

Cooper Companies

ALGN (0.9%)

Align Technology

LNTH (0.5%)

Lantheus

Higher Rev Chg 3Y Avg (Value for HAE: 5.5%)

LNTH (19.2%)

Lantheus

MMSI (9.6%)

Merit Medical Systems

BLFS (8.9%)

BioLife Solutions

NEOG (7.5%)

Neogen

COO (7.1%)

Cooper Companies

Higher Op Mgn LTM (Value for HAE: 18.0%)

WST (20.7%)

West Pharmaceutical Services

LNTH (20.5%)

Lantheus

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for HAE: 5.5% | 2.1x)

UNH (11.4% | 0.6x)

UnitedHealth

HCA (7.9% | 1.5x)

HCA Healthcare

MCK (13.3% | 0.3x)

McKesson

CVS (7.7% | 0.2x)

CVS Health

CI (15.3% | 0.3x)

Cigna

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for HAE: 5.5% | 11.5x)

HCA (7.9% | 9.6x)

HCA Healthcare

CVS (7.7% | 9.6x)

CVS Health

UHS (9.0% | 5.8x)

Universal Health Services

EHC (10.9% | 10.3x)

Encompass Health

HALO (28.5% | 9.8x)

Halozyme Therapeutics

Higher Rev Chg LTM (Value for HAE: -4.0%)

LLY (44.7%)

Eli Lilly

UNH (11.8%)

UnitedHealth

ABBV (8.6%)

AbbVie

JNJ (6.0%)

Johnson & Johnson

MRK (1.3%)

Merck

Higher Rev Chg 3Y Avg (Value for HAE: 5.5%)

LLY (32.1%)

Eli Lilly

ISRG (17.4%)

Intuitive Surgical

AMGN (11.9%)

Amgen

UNH (11.4%)

UnitedHealth

SYK (10.8%)

Stryker

Higher Op Mgn LTM (Value for HAE: 18.0%)

LLY (45.6%)

Eli Lilly

MRK (34.0%)

Merck

ABBV (32.8%)

AbbVie

JNJ (27.2%)

Johnson & Johnson

AMGN (24.7%)

Amgen

Higher CFO/Rev LTM (Value for HAE: 25.7%)

GILD (34.0%)

Gilead Sciences

ABBV (31.1%)

AbbVie

AMGN (27.1%)

Amgen

JNJ (26.0%)

Johnson & Johnson

LLY (25.8%)

Eli Lilly

Higher FCF/Rev LTM (Value for HAE: 23.4%)

GILD (32.1%)

Gilead Sciences

ABBV (29.1%)

AbbVie

BMY (26.7%)

Bristol-Myers Squibb

VRTX (26.6%)

Vertex Pharmaceuticals

ISRG (24.7%)

Intuitive Surgical

Higher Total Yield (Value for HAE: 6.4%)

MRK (8.7%)

Merck

UNH (7.2%)

UnitedHealth

GILD (7.1%)

Gilead Sciences

JNJ (6.7%)

Johnson & Johnson

AMGN (6.7%)

Amgen

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for HAE: 5.5% | 2.1x)

COST (6.9% | 1.6x)

Costco Wholesale

BA (12.3% | 1.9x)

Boeing

ENB (8.8% | 1.8x)

Enbridge

PGR (21.0% | 1.3x)

Progressive

GD (10.1% | 1.8x)

General Dynamics

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for HAE: 5.5% | 11.5x)

ENB (8.8% | 10.3x)

Enbridge

ADBE (10.8% | 10.5x)

Adobe

B (16.0% | 8.8x)

Barrick Mining

TRP (7.4% | 9.9x)

TC Energy

APO (66.8% | 7.7x)

Apollo Global Management

Higher Rev Chg LTM (Value for HAE: -4.0%)

NVDA (65.5%)

NVIDIA

MSFT (16.7%)

Microsoft

GOOGL (15.1%)

Alphabet

AMZN (12.4%)

Amazon.com

AAPL (10.1%)

Apple

Higher Rev Chg 3Y Avg (Value for HAE: 5.5%)

NVDA (101.8%)

NVIDIA

AVGO (26.2%)

Broadcom

MSFT (14.4%)

Microsoft

GOOGL (12.5%)

Alphabet

AMZN (11.7%)

Amazon.com

Higher Op Mgn LTM (Value for HAE: 18.0%)

NVDA (60.4%)

NVIDIA

MSFT (46.7%)

Microsoft

AVGO (41.5%)

Broadcom

AAPL (32.4%)

Apple

GOOGL (32.0%)

Alphabet

Higher CFO/Rev LTM (Value for HAE: 25.7%)

MSFT (52.5%)

Microsoft

NVDA (47.6%)

NVIDIA

AVGO (43.5%)

Broadcom

GOOGL (40.9%)

Alphabet

AAPL (31.1%)

Apple

Higher FCF/Rev LTM (Value for HAE: 23.4%)

V (55.4%)

Visa

NVDA (44.8%)

NVIDIA

AVGO (42.3%)

Broadcom

AAPL (28.3%)

Apple

MSFT (25.3%)

Microsoft

Higher Total Yield (Value for HAE: 6.4%)

BAC (7.9%)

Bank of America

HD (7.0%)

Home Depot

XOM (7.0%)

Exxon Mobil

JPM (6.7%)

JPMorgan Chase

CVX (6.6%)

Chevron

Best Bets in Health Care

What You Pay

P/EBIT (Value for HAE: 10.9x)

RPRX (12.7x)

Royalty Pharma

DOCS (16.6x)

Doximity

VEEV (28.1x)

Veeva Systems

HALO (16.3x)

Halozyme Therapeutics

UTHR (14.4x)

United Therapeutics

CPRX (12.2x)

Catalyst Pharmaceuticals

BMY (10.8x)

Bristol-Myers Squibb

RMD (18.0x)

ResMed

AMGN (16.3x)

Amgen

PBH (8.8x)

Prestige Consumer Healthcare

P/E (Value for HAE: 15.6x)

RPRX (26.8x)

Royalty Pharma

DOCS (16.6x)

Doximity

VEEV (28.3x)

Veeva Systems

HALO (24.9x)

Halozyme Therapeutics

UTHR (18.7x)

United Therapeutics

CPRX (14.7x)

Catalyst Pharmaceuticals

BMY (17.1x)

Bristol-Myers Squibb

RMD (22.4x)

ResMed

AMGN (24.8x)

Amgen

PBH (14.6x)

Prestige Consumer Healthcare

What You Get

Rev Chg 3Y Avg (Value for HAE: 5.5%)

RPRX (2.1%)

Royalty Pharma

DOCS (16.7%)

Doximity

VEEV (14.1%)

Veeva Systems

HALO (28.5%)

Halozyme Therapeutics

UTHR (18.1%)

United Therapeutics

CPRX (43.1%)

Catalyst Pharmaceuticals

BMY (1.5%)

Bristol-Myers Squibb

RMD (12.9%)

ResMed

AMGN (11.9%)

Amgen

PBH (-0.1%)

Prestige Consumer Healthcare

Rev Chg LTM (Value for HAE: -4.0%)

RPRX (5.1%)

Royalty Pharma

DOCS (15.9%)

Doximity

VEEV (16.3%)

Veeva Systems

HALO (37.6%)

Halozyme Therapeutics

UTHR (10.6%)

United Therapeutics

CPRX (19.8%)

Catalyst Pharmaceuticals

BMY (-0.2%)

Bristol-Myers Squibb

RMD (9.6%)

ResMed

AMGN (10.0%)

Amgen

PBH (-1.3%)

Prestige Consumer Healthcare

Rev Chg Q (Value for HAE: -2.7%)

RPRX (4.8%)

Royalty Pharma

DOCS (9.8%)

Doximity

VEEV (16.0%)

Veeva Systems

HALO (51.6%)

Halozyme Therapeutics

UTHR (7.4%)

United Therapeutics

CPRX (7.6%)

Catalyst Pharmaceuticals

BMY (1.3%)

Bristol-Myers Squibb

RMD (11.0%)

ResMed

AMGN (8.6%)

Amgen

PBH (-2.4%)

Prestige Consumer Healthcare

FCF/Rev 3Y Avg (Value for HAE: 12.1%)

RPRX (118.0%)

Royalty Pharma

DOCS (41.6%)

Doximity

VEEV (40.8%)

Veeva Systems

HALO (38.8%)

Halozyme Therapeutics

UTHR (34.1%)

United Therapeutics

CPRX (33.2%)

Catalyst Pharmaceuticals

BMY (27.9%)

Bristol-Myers Squibb

RMD (27.3%)

ResMed

AMGN (26.4%)

Amgen

PBH (22.3%)

Prestige Consumer Healthcare

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	How To Earn 8.8% Yield While Waiting to Buy HAE 40% Cheaper	12/30/2026
2	Haemonetics Earnings Notes	12/29/2026
3	Day 11 of Gains Streak for Haemonetics Stock with 49% Return (vs. -5.3% YTD) [11/13/2025]TREFISDASH	11/14/2025
4	Day 10 of Gains Streak for Haemonetics Stock with 48% Return (vs. -6.4% YTD) [11/12/2025]TREFISDASH	11/13/2025
5	Why Haemonetics Stock Jumped 30%?	11/07/2025
6	Can Haemonetics Stock Hold Up When Markets Turn?	10/17/2025
7	Is The 29.8% Decline In Haemonetics (HAE) Stock A Dip Buying Opportunity?	09/03/2025
8	ARTICLES
9	The Smart Way to Own HAE: Collect 8.8% Before You Even Buy	12/30/2025
10	Haemonetics Stock Rockets 49% With 11-Day Winning Streak	11/14/2025
11	10-Day Rally Sends Haemonetics Stock Up 48%	11/13/2025
12	Does Haemonetics Stock Lead the Pack?	11/07/2025
13	Haemonetics Stock Surged 30%, Here’s Why	11/07/2025

	Title
0	DASHBOARDS
1	How To Earn 8.8% Yield While Waiting to Buy HAE 40% Cheaper
2	Haemonetics Earnings Notes
3	Day 11 of Gains Streak for Haemonetics Stock with 49% Return (vs. -5.3% YTD) [11/13/2025]TREFISDASH
4	Day 10 of Gains Streak for Haemonetics Stock with 48% Return (vs. -6.4% YTD) [11/12/2025]TREFISDASH
5	Why Haemonetics Stock Jumped 30%?
6	Can Haemonetics Stock Hold Up When Markets Turn?
7	Is The 29.8% Decline In Haemonetics (HAE) Stock A Dip Buying Opportunity?
8	ARTICLES
9	The Smart Way to Own HAE: Collect 8.8% Before You Even Buy
10	Haemonetics Stock Rockets 49% With 11-Day Winning Streak
11	10-Day Rally Sends Haemonetics Stock Up 48%
12	Does Haemonetics Stock Lead the Pack?
13	Haemonetics Stock Surged 30%, Here’s Why

Trade Ideas

Select ideas related to HAE.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
PGNY_3312026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03312026	PGNY	Progyny	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	0.0%	0.0%	0.0%
CNC_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03272026	CNC	Centene	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.3%	2.3%	-0.6%
OSCR_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03272026	OSCR	Oscar Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.0%	3.0%	-2.6%
WAT_3202026_Monopoly_xInd_xCD_Getting_Cheaper	03202026	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	-0.4%	-0.4%	-3.3%
GILD_3202026_Quality_Momentum_RoomToRun_10%	03202026	GILD	Gilead Sciences	Quality	Q \| Momentum \| UpsideQuality Stocks with Momentum and Upside Buying quality stocks with strong momentum but still having room to run	1.6%	1.6%	-2.2%
HAE_2202026_Dip_Buyer_FCFYield	02202026	HAE	Haemonetics	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	-7.9%	-7.9%	-11.7%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
EOSE	Eos Energy Enterprises	1.8	29.6%	-48.1%
YSS	York Space Systems	4.5	28.8%	7.1%
MPLT	MapLight Therapeutics	1.2	21.3%	67.4%
STAA	Staar Surgical	1.3	20.7%	9.2%
AXTI	AXT	2.8	18.7%	286.1%
FNMA	Federal National Mortgage Association Fannie Mae	46.1	18.6%	-26.7%
OGN	Organon	1.8	17.9%	-3.4%
FMCC	Federal Home Loan Mortgage	22.5	17.6%	-31.5%
IOVA	Iovance Biotherapeutics	1.6	15.6%	46.9%
ORIC	ORIC Pharmaceuticals	1.1	14.7%	26.9%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
SMPL	Simply Good Foods	1.2	-18.1%	-41.2%
TPL	Texas Pacific Land	26.1	-15.7%	31.7%
QLYS	Qualys	2.7	-12.2%	-42.3%
SNOW	Snowflake	45.3	-11.8%	-39.7%
ZS	Zscaler	19.5	-11.3%	-45.7%
OKTA	Okta	12.0	-10.9%	-21.6%
SAIL	SailPoint	6.2	-10.9%	-45.3%
RBRK	Rubrik	9.3	-10.6%	-39.6%
BLLN	BillionToOne	3.8	-10.3%	0.8%
AXON	Axon Enterprise	27.8	-10.3%	-38.1%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
CAR	Avis Budget	10.5	74.7%	131.5%
AEHR	Aehr Test Systems	2.1	73.9%	241.1%
AAOI	Applied Optoelectronics	9.4	54.4%	282.4%
YSS	York Space Systems	4.5	52.6%	7.1%
SLNO	Soleno Therapeutics	2.8	42.0%	13.4%
MPLT	MapLight Therapeutics	1.2	41.2%	67.4%
RLAY	Relay Therapeutics	2.6	39.3%	77.3%
ORIC	ORIC Pharmaceuticals	1.1	38.9%	26.9%
HUT	Hut 8	6.9	33.9%	38.0%
AXTI	AXT	2.8	33.9%	286.1%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
REPL	Replimune	0.5	-22.3%	-39.2%
TBN	Tamboran Resources	0.7	-21.4%	29.8%
GEVO	Gevo	0.5	-20.3%	-4.5%
VRDN	Viridian Therapeutics	1.5	-19.7%	-50.6%
SEDG	SolarEdge Technologies	2.5	-19.3%	45.0%
ENPH	Enphase Energy	4.1	-18.3%	-2.5%
RYAM	Rayonier Advanced Materials	0.6	-17.8%	55.5%
SAIL	SailPoint	6.2	-17.2%	-45.3%
AXON	Axon Enterprise	27.8	-17.1%	-38.1%
SMPL	Simply Good Foods	1.2	-16.9%	-41.2%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
XLO	Xilio Therapeutics	0.6	1428.6%	-4.5%
CAR	Avis Budget	10.5	210.1%	131.5%
SATL	Satellogic	0.9	132.3%	285.0%
APLS	Apellis Pharmaceuticals	5.1	107.0%	61.8%
FLY	Firefly Aerospace	6.0	93.8%	67.9%
LWLG	Lightwave Logic	1.1	93.6%	160.5%
ORKA	Oruka Therapeutics	3.4	88.8%	109.8%
TH	Target Hospitality	1.5	86.7%	86.0%
KODK	Eastman Kodak	1.2	76.7%	45.2%
FBYD	Falcons Beyond Global	0.4	73.4%	-27.9%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
WVE	WAVE Life Sciences	1.3	-47.9%	-57.9%
TE	T1 Energy	0.7	-47.6%	-37.4%
VRDN	Viridian Therapeutics	1.5	-47.3%	-50.6%
BUR	Burford Capital	1.0	-46.9%	-50.7%
MAZE	Maze Therapeutics	1.3	-45.4%	-32.7%
FRMI	Fermi	2.9	-40.1%	-39.8%
ADMA	ADMA Biologics	2.4	-37.2%	-45.5%
BOBS	Bobs Discount Furniture	1.5	-36.6%	-32.7%
LMRI	Lumexa Imaging	0.9	-35.6%	-49.7%
AXON	Axon Enterprise	27.8	-33.7%	-38.1%

Peer Comparisons

Peers to compare with:

Financials

	HAE	ICUI	LIVN	BAX	BDX	MDT	Median
Name	Haemonet.	ICU Medi.	LivaNova	Baxter I.	Becton D.	Medtronic
Mkt Price	58.42	125.83	63.37	17.30	155.46	87.91	75.64
Mkt Cap	2.7	3.1	3.5	8.9	44.4	112.8	6.2
Rev LTM	1,318	2,231	1,388	11,244	21,924	35,483	6,738
Op Inc LTM	237	109	199	177	3,104	6,611	218
FCF LTM	308	83	173	323	2,631	5,410	316
FCF 3Y Avg	160	90	116	724	2,738	5,269	442
CFO LTM	339	180	254	845	3,394	7,285	592
CFO 3Y Avg	222	183	171	1,197	3,491	7,016	709

Growth & Margins

	HAE	ICUI	LIVN	BAX	BDX	MDT	Median
Name	Haemonet.	ICU Medi.	LivaNova	Baxter I.	Becton D.	Medtronic
Rev Chg LTM	-4.0%	-6.3%	10.7%	5.7%	6.2%	6.9%	6.0%
Rev Chg 3Y Avg	5.5%	-0.6%	10.8%	4.5%	5.4%	4.9%	5.1%
Rev Chg Q	-2.7%	-14.1%	12.1%	8.0%	1.6%	8.7%	4.8%
QoQ Delta Rev Chg LTM	-0.7%	-3.8%	2.9%	2.0%	0.4%	2.1%	1.2%
Op Mgn LTM	18.0%	4.9%	14.4%	1.6%	14.2%	18.6%	14.3%
Op Mgn 3Y Avg	15.1%	3.7%	8.8%	3.5%	13.3%	18.5%	11.1%
QoQ Delta Op Mgn LTM	0.8%	-0.7%	-0.0%	-2.2%	0.5%	-0.7%	-0.3%
CFO/Rev LTM	25.7%	8.1%	18.3%	7.5%	15.5%	20.5%	16.9%
CFO/Rev 3Y Avg	16.9%	8.0%	13.1%	10.3%	16.9%	20.8%	15.0%
FCF/Rev LTM	23.4%	3.7%	12.5%	2.9%	12.0%	15.2%	12.2%
FCF/Rev 3Y Avg	12.1%	3.9%	8.9%	6.1%	13.3%	15.7%	10.5%

Valuation

	HAE	ICUI	LIVN	BAX	BDX	MDT	Median
Name	Haemonet.	ICU Medi.	LivaNova	Baxter I.	Becton D.	Medtronic
Mkt Cap	2.7	3.1	3.5	8.9	44.4	112.8	6.2
P/S	2.1	1.4	2.5	0.8	2.0	3.2	2.0
P/EBIT	10.9	31.8	-20.2	-41.3	17.2	18.0	14.0
P/E	15.6	4,243.8	-14.3	-9.3	25.3	24.4	20.0
P/CFO	8.1	17.3	13.6	10.5	13.1	15.5	13.3
Total Yield	6.4%	0.0%	-7.0%	-6.9%	6.6%	7.3%	3.2%
Dividend Yield	0.0%	0.0%	0.0%	3.9%	2.7%	3.2%	1.3%
FCF Yield 3Y Avg	4.1%	2.8%	4.0%	4.5%	4.3%	4.7%	4.2%
D/E	0.4	0.4	0.1	1.1	0.4	0.2	0.4
Net D/E	0.3	0.3	-0.1	0.9	0.4	0.2	0.3

Returns

	HAE	ICUI	LIVN	BAX	BDX	MDT	Median
Name	Haemonet.	ICU Medi.	LivaNova	Baxter I.	Becton D.	Medtronic
1M Rtn	-7.0%	-5.0%	2.3%	-0.9%	-5.1%	-1.4%	-3.2%
3M Rtn	-30.5%	-17.0%	-2.4%	-16.3%	-3.0%	-10.2%	-13.3%
6M Rtn	16.5%	7.6%	21.6%	-23.1%	5.8%	-7.5%	6.7%
12M Rtn	-4.3%	-16.7%	77.4%	-43.0%	-3.3%	6.4%	-3.8%
3Y Rtn	-30.2%	-27.4%	47.3%	-56.0%	-17.5%	20.8%	-22.5%
1M Excs Rtn	-7.7%	-5.6%	1.7%	-1.6%	-5.8%	-2.0%	-3.8%
3M Excs Rtn	-28.2%	-14.9%	-0.5%	-13.8%	-0.4%	-9.8%	-11.8%
6M Excs Rtn	17.0%	4.9%	19.9%	-26.0%	2.3%	-10.8%	3.6%
12M Excs Rtn	-35.7%	-46.4%	44.2%	-73.6%	-36.1%	-25.7%	-35.9%
3Y Excs Rtn	-94.9%	-87.3%	-16.9%	-119.1%	-80.8%	-43.8%	-84.1%

Comparison Analyses

	Title
0	Haemonetics vs. Merit Medical Systems: With Return Forecast Of 41%, Haemonetics Is A Better Bet
1	Haemonetics vs. Integra LifeSciences: With Return Forecast Of 56%, Integra LifeSciences Is A Better Bet
2	With 20% Gains On The Table, CNMD May Outshine HAE
3	Haemonetics vs. Alnylam Pharmaceuticals: With Return Forecast Of 85%, Alnylam Pharmaceuticals Is A Better Bet
4	Haemonetics vs. ABIOMED: With Return Forecast Of 68%, ABIOMED Is A Better Bet
5	Haemonetics vs. Paycom Software: With Return Forecast Of 92%, Paycom Software Is A Better Bet
6	Haemonetics vs. Kulicke and Soffa Industries: Similar Market Cap, Similar Bets
7	Haemonetics vs. Installed Building Products: Similar Market Cap, But Installed Building Products Is A Better Bet
8	Haemonetics vs Allete: Similar Market Cap; Which Stock Is A Better Bet?
9	Haemonetics vs ProShares UltraShort DJ: Similar Market Cap; Which Stock Is A Better Bet?

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 3/29	LTM	2025	2024	2023	2022	2021	2020
Period End	12/27/2025	3/29/2025	3/30/2024	4/1/2023	4/2/2022	4/3/2021	3/28/2020
Filing Date	2/5/2026	5/21/2025	5/20/2024	5/22/2023	5/25/2022	5/26/2021	5/20/2020
Key Financials
Total Revenue	1,318	1,361	1,309	1,169	993	870	988
EBITDA	364	337	262	249	178	174	214
Operating Income	237	201	173	156	71	57	146
Net Income	175	168	118	115	43	79	77
EPS	3.66	3.33	2.32	2.27	0.85	1.57	1.51
Growth Rates
Total Revenue Growth	-4.0%	4.0%	12.0%	17.7%	14.1%	-11.9%	2.2%
EBITDA Growth	23.1%	28.7%	5.1%	39.7%	2.6%	-18.5%	10.7%
Operating Income Growth	24.1%	16.1%	11.3%	118.8%	25.0%	-61.0%	74.6%
Net Income Growth	34.9%	42.6%	1.9%	166.1%	-45.4%	3.8%	39.1%
Margins
EBITDA Margin	27.6%	24.8%	20.0%	21.3%	18.0%	20.0%	21.6%
Operating Income Margin	18.0%	14.8%	13.2%	13.3%	7.2%	6.5%	14.8%
Net Income Margin	13.3%	12.3%	9.0%	9.9%	4.4%	9.1%	7.7%
Cash & Debt
Total Cash	363	307	179	284	259	192	137
Total Debt	1,225	1,225	808	766	774	715	442
Net Debt / (Cash)	861	918	629	481	514	523	305
Cash Flows
Net Cash from Operations	339	182	182	273	172	109	158
Free Cash from Operations	308	142	144	82	76	72	109
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	150	225	-0	75	-0	-0	175

$ Mil \| FY: 3/29	2026Q3	2026Q2	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4
Period End	12/27/2025	9/27/2025	6/28/2025	3/29/2025	12/28/2024	9/28/2024	6/29/2024	3/30/2024	12/30/2023	9/30/2023	7/1/2023	4/1/2023
Filing Date	2/5/2026	11/6/2025	8/7/2025	5/21/2025	2/6/2025	11/7/2024	8/8/2024	5/20/2024	2/8/2024	11/2/2023	8/8/2023	5/22/2023
Key Financials Quarterly
Total Revenue	339	327	321	331	349	346	336	343	336	318	311	304
Ebitda	95	87	83	100	88	81	69	58	70	58	77	59
Operating Income	68	67	54	48	59	54	40	38	46	35	54	35
Net Income	45	39	34	58	37	34	38	20	31	25	41	29
EPS	0.96	0.81	0.71	1.18	0.75	0.66	0.75	0.40	0.62	0.49	0.81	0.58
Key Financials TTM
Total Revenue TTM	1,318	1,328	1,346	1,361	1,374	1,361	1,334	1,309	1,270	1,239	1,219	1,169
Ebitda TTM	364	357	351	337	295	277	254	262	264	261	273	249
Operating Income TTM	237	228	215	201	191	178	159	173	170	167	179	156
Net Income TTM	175	168	163	168	130	124	115	118	127	128	137	115
Growth Rates Quarterly
Total Revenue Growth	-2.7%	-5.3%	-4.4%	-3.7%	3.7%	8.6%	8.0%	12.8%	10.1%	7.0%	19.1%	14.9%
EBITDA Growth	7.6%	7.2%	19.9%	72.9%	26.7%	38.8%	-10.2%	-2.6%	4.0%	-16.9%	44.1%	34.3%
Operating Income Growth	15.4%	24.0%	35.5%	25.9%	28.4%	53.2%	-25.9%	10.0%	6.2%	-24.5%	74.4%	81.6%
Net Income Growth	19.3%	14.3%	-11.3%	184.7%	20.0%	35.8%	-6.5%	-30.7%	-5.2%	-25.0%	106.5%	201.6%
Margins Quarterly
EBITDA Margin	28.0%	26.5%	25.7%	30.1%	25.3%	23.4%	20.5%	16.8%	20.7%	18.3%	24.6%	19.4%
Operating Income Margin	20.1%	20.5%	16.8%	14.6%	16.9%	15.7%	11.8%	11.2%	13.7%	11.1%	17.2%	11.5%
Net Income Margin	13.2%	11.8%	10.6%	17.5%	10.8%	9.8%	11.4%	5.9%	9.3%	7.8%	13.2%	9.7%
Cash & Debt
Total Cash	363	296	293	307	321	299	344	179	194	351	286	284
Total Debt	1,225	1,225	1,225	1,225	1,225	1,225	1,224	808	871	762	765	766
Net Debt / (Cash)	861	928	932	918	904	926	879	629	677	411	479	481
Cash Flows Quarterly
FCF from Operations	94	111	17	117	44	49	-27	64	-1	99	19	80
Cash Flows TTM
FCF from Operations TTM	339	289	227	182	129	85	135	182	197	262	250	273
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	150	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	14.6%	14.0%	11.1%	11.4%	12.5%	11.4%	9.3%	10.9%	10.2%	10.8%	16.1%	12.0%
Return on Invested Capital (ROIC) TTM
ROIC TTM	13.2%	12.3%	11.5%	11.5%	10.6%	9.7%	8.9%	10.9%	10.4%	13.5%	13.7%	12.1%

Segment Financials

Revenue by Segment

$ Mil	2025	2024	2023	2022
Plasma	570	500	352	333
Hospital	456	378	322	211
Blood Center	283	289	295	307
Effect of exchange rates		-21	4	-2
Service		21	21	21
Total	1,309	1,169	993	870

Operating Income by Segment

$ Mil	2025	2024	2023	2022
Plasma	182	279	183	172
Hospital	52	154	130	84
Blood Center	42	132	137	142
Contingent Consideration	0
Acquisition, integration and divestiture related costs	-11
Digital transformation costs	-16	-5	0
Restructuring and restructuring related costs	-24		-29	-16
Other	-26
Amortization of acquired assets	-35	-33	-47	-33
Amortization of fair value inventory step-up		0
Corporate expenses		-355	-281	-257
Effect of exchange rates		8	19	13
Gains on divestiture and sale of assets		0	10	33
Impairment of intangible assets		0
Integration and transaction costs		0	-22	-18
Litigation-related charges		-5	-1	-1
Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) costs		-10	-11
Restructuring costs		-1
Restructuring related costs		-11
Write downs of certain in-process assets and PCS2 related charges		1	-6	-26
European Medical Device Regulation costs				-4
Total	165	156	81	90

Price Behavior

Price Behavior

Market Price	$58.42
Market Cap ($ Bil)	2.7
First Trading Date	05/10/1991
Distance from 52W High	-33.0%
	50 Days	200 Days
DMA Price	$60.58	$64.74
DMA Trend	down	down
Distance from DMA	-3.6%	-9.8%
	3M	1YR
Volatility	33.4%	51.2%
Downside Capture	0.58	0.50
Upside Capture	-100.73	64.04
Correlation (SPY)	-6.8%	20.7%

HAE Betas & Captures as of 3/31/2026

	1M	2M	3M	6M	1Y	3Y
Beta	0.06	-0.46	-0.14	-0.10	0.62	0.62
Up Beta	-1.05	-3.89	-2.59	-0.24	0.86	0.65
Down Beta	-0.87	-0.19	-0.12	-0.48	0.10	0.36
Up Capture	-37%	-65%	-62%	34%	57%	28%
Bmk +ve Days	7	16	27	65	139	424
Stock +ve Days	7	20	27	69	128	384
Down Capture	107%	58%	117%	-2%	98%	97%
Bmk -ve Days	12	23	33	58	110	323
Stock -ve Days	15	22	36	57	121	363

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with HAE
HAE	0.6%	52.1%	0.19	-
Sector ETF (XLV)	12.6%	16.8%	0.54	27.2%
Equity (SPY)	29.1%	17.4%	1.36	21.5%
Gold (GLD)	61.3%	27.8%	1.72	-6.2%
Commodities (DBC)	26.9%	16.7%	1.41	2.6%
Real Estate (VNQ)	17.7%	15.4%	0.86	21.6%
Bitcoin (BTCUSD)	-10.9%	43.9%	-0.14	5.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with HAE
HAE	-12.0%	43.3%	-0.15	-
Sector ETF (XLV)	6.7%	14.6%	0.28	27.9%
Equity (SPY)	11.4%	17.0%	0.52	29.5%
Gold (GLD)	22.2%	17.8%	1.02	0.5%
Commodities (DBC)	11.5%	18.8%	0.50	6.0%
Real Estate (VNQ)	3.7%	18.8%	0.10	26.4%
Bitcoin (BTCUSD)	3.6%	56.5%	0.29	12.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with HAE
HAE	5.4%	39.8%	0.27	-
Sector ETF (XLV)	10.0%	16.5%	0.50	34.3%
Equity (SPY)	13.9%	17.9%	0.67	37.1%
Gold (GLD)	14.1%	15.9%	0.74	-0.3%
Commodities (DBC)	8.5%	17.6%	0.40	12.8%
Real Estate (VNQ)	5.1%	20.7%	0.21	29.9%
Bitcoin (BTCUSD)	67.1%	66.9%	1.06	11.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	3132026
Short Interest: Shares Quantity	1.9 Mil
Short Interest: % Change Since 2282026	-29.7%
Average Daily Volume	0.8 Mil
Days-to-Cover Short Interest	2.4 days
Basic Shares Quantity	46.8 Mil
Short % of Basic Shares	4.1%

Returns Analyses

	Title
0	Can Haemonetics Stock Hold Up When Markets Turn?
1	Haemonetics Stock Return Comparison
2	[10/13/2021] Haemonetics (HAE) Stock Price Forecast: AI Forecasts HAE Stock Price To Be Around $71.20 In A Month (Up 1.9%)
3	Haemonetics Total Shareholder Return (TSR): 65.2% in 2023 and -9.7% 3-yr returns (below peer average)
4	Haemonetics (HAE) Stock Return: AI Predicts HAE Average and Excess Return After a Fall or Rise

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
2/5/2026	-1.4%	-12.8%	-2.8%
11/6/2025	32.3%	44.2%	64.1%
8/7/2025	-26.6%	-28.9%	-28.2%
5/8/2025	5.9%	6.8%	9.7%
2/6/2025	-11.6%	-13.9%	-3.6%
11/7/2024	10.7%	17.4%	3.9%
8/8/2024	-10.8%	-14.6%	-14.6%
5/9/2024	-0.7%	3.5%	-8.2%
...
SUMMARY STATS
# Positive	12	12	14
# Negative	11	11	9
Median Positive	8.1%	9.9%	8.0%
Median Negative	-6.8%	-7.6%	-8.2%
Max Positive	32.3%	44.2%	64.1%
Max Negative	-26.6%	-28.9%	-28.2%

	Forward Returns
2/5/2026	-1.4%	-12.8%	-2.8%
11/6/2025	32.3%	44.2%	64.1%
8/7/2025	-26.6%	-28.9%	-28.2%
5/8/2025	5.9%	6.8%	9.7%
2/6/2025	-11.6%	-13.9%	-3.6%
11/7/2024	10.7%	17.4%	3.9%
8/8/2024	-10.8%	-14.6%	-14.6%
5/9/2024	-0.7%	3.5%	-8.2%
2/8/2024	1.3%	-7.6%	3.2%
11/2/2023	-1.1%	-0.3%	-2.5%
8/8/2023	1.5%	4.7%	0.1%
5/11/2023	3.3%	2.9%	6.1%
2/7/2023	-5.9%	-7.0%	-10.5%
11/7/2022	3.6%	-1.7%	4.3%
8/10/2022	8.9%	12.9%	11.6%
5/10/2022	10.4%	16.9%	33.1%
2/8/2022	16.2%	23.8%	26.5%
11/9/2021	-15.4%	-18.6%	-22.0%
8/11/2021	7.3%	2.6%	13.7%
5/13/2021	-13.4%	-5.5%	0.4%
2/2/2021	13.0%	21.3%	6.3%
11/4/2020	-6.8%	7.0%	10.4%
5/5/2020	-3.3%	-4.4%	-6.6%
SUMMARY STATS
# Positive	12	12	14
# Negative	11	11	9
Median Positive	8.1%	9.9%	8.0%
Median Negative	-6.8%	-7.6%	-8.2%
Max Positive	32.3%	44.2%	64.1%
Max Negative	-26.6%	-28.9%	-28.2%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
12/31/2025	02/05/2026	10-Q
09/30/2025	11/06/2025	10-Q
06/30/2025	08/07/2025	10-Q
03/31/2025	05/21/2025	10-K
12/31/2024	02/06/2025	10-Q
09/30/2024	11/07/2024	10-Q
06/30/2024	08/08/2024	10-Q
03/31/2024	05/20/2024	10-K
12/31/2023	02/08/2024	10-Q
09/30/2023	11/02/2023	10-Q
06/30/2023	08/08/2023	10-Q
03/31/2023	05/22/2023	10-K
12/31/2022	02/07/2023	10-Q
09/30/2022	11/08/2022	10-Q
06/30/2022	08/10/2022	10-Q
03/31/2022	05/25/2022	10-K

Recent Forward Guidance [BETA]

Latest: Q3 2026 Earnings Reported 2/5/2026

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
2026 Adjusted Operating Margin	26.0%	26.5%	27.0%	0	0	Affirmed	Guidance: 26.5% for 2026
2026 Adjusted EPS	4.9	4.95	5	1.0%		Raised	Guidance: 4.9 for 2026
2026 Free Cash Flow	200.00 Mil	210.00 Mil	220.00 Mil	10.5%		Raised	Guidance: 190.00 Mil for 2026

Prior: Q2 2026 Earnings Reported 11/6/2025

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
2026 Adjusted Operating Margin	26.0%	26.5%	27.0%	0	0	Affirmed	Guidance: 26.5% for 2026
2026 Adjusted EPS	4.8	4.9	5	1.0%		Raised	Guidance: 4.85 for 2026
2026 Free Cash Flow	170.00 Mil	190.00 Mil	210.00 Mil	5.6%		Raised	Guidance: 180.00 Mil for 2026
2026 Revenue Growth	-4.0%	-2.5%	-1.0%

Insider Activity

Expand for More

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Kroll, Mark W		Direct	Buy	11122025	70.56	1,400	98,784	1,746,854	Form

HAE Trade Sentinel

Stock Conviction

null

CONVICTION RATIONALE

null

STOCK ARCHETYPE

null

INVESTMENT THESIS

null

Mechanism: null

Supporting Evidence:

PRIMARY RISK

null

Mechanism: null

Supporting Evidence:

Key KPI Watchlist

KPI	Threshold	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

null

Diversification Alternatives

How Is The Market Pricing HAE?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What HAE Makes & Who Pays

TTM figures based on

HAE Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Haemonetics (HAE)

Market Price (4/10/2026): $58.42 | Market Cap: $2.7 BilSector: Health Care | Industry: Health Care Supplies

Haemonetics (HAE)

Market Price (4/10/2026): $58.42Market Cap: $2.7 BilSector: Health CareIndustry: Health Care Supplies

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Haemonetics (HAE)

Interactive Breakdown

Better Bets vs. Haemonetics (HAE)

INDUSTRY: Health Care Supplies

Higher Rev Chg LTM (Value for HAE: -4.0%)

Higher Rev Chg 3Y Avg (Value for HAE: 5.5%)

Higher Op Mgn LTM (Value for HAE: 18.0%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for HAE: 5.5% | 2.1x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for HAE: 5.5% | 11.5x)

Higher Rev Chg LTM (Value for HAE: -4.0%)

Higher Rev Chg 3Y Avg (Value for HAE: 5.5%)

Higher Op Mgn LTM (Value for HAE: 18.0%)

Higher CFO/Rev LTM (Value for HAE: 25.7%)

Higher FCF/Rev LTM (Value for HAE: 23.4%)

Higher Total Yield (Value for HAE: 6.4%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for HAE: 5.5% | 2.1x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for HAE: 5.5% | 11.5x)

Higher Rev Chg LTM (Value for HAE: -4.0%)

Higher Rev Chg 3Y Avg (Value for HAE: 5.5%)

Higher Op Mgn LTM (Value for HAE: 18.0%)

Higher CFO/Rev LTM (Value for HAE: 25.7%)

Higher FCF/Rev LTM (Value for HAE: 23.4%)

Higher Total Yield (Value for HAE: 6.4%)

Best Bets in Health Care

P/EBIT (Value for HAE: 10.9x)

P/E (Value for HAE: 15.6x)

Rev Chg 3Y Avg (Value for HAE: 5.5%)

Rev Chg LTM (Value for HAE: -4.0%)

Rev Chg Q (Value for HAE: -2.7%)

FCF/Rev 3Y Avg (Value for HAE: 12.1%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Market Price (4/10/2026): $58.42 | Market Cap: $2.7 Bil
Sector: Health Care | Industry: Health Care Supplies

Market Price (4/10/2026): $58.42
Market Cap: $2.7 Bil
Sector: Health Care
Industry: Health Care Supplies